03 June 2004
Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products
Zofia Dzierżewicz, Beata Cwalina, Ludmiła Węglarz, Beata Wiśniowska, Joanna SzczerbaMed Sci Monit 2004; 10(6): BR185-190 :: ID: 11672
Abstract
Background:Desulfovibrio desulfuricans intestinal bacteria may contribute to toxic hydrogen sulfide production in the human gut. Our objective was to examine whether the D. desulfuricans strains isolated from the human body are susceptible to sulfasalazine (SAS) and the products of its biotransformation, i.e. 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), in order to determine the relationship between the strains’ susceptibility to SAS and their ability to reduce the azo bond within this drug.
Material/Methods: Six wild strains of D. desulfuricans (isolated from feces and biopsy specimens from patients with colitis ulcerosa, Crohn’s disease, irritable bowel syndrome, colonic diverticula, primary biliary cirrhosis, or tubular adenomas of the colon) were cultured in the presence of SAS, 5-ASA, and SP. Growth inhibition coefficients were compared with coefficients of inhibition of the azo-bond reduction in SAS.
Results: The D. desulfuricans strains present in the human digestive tract were susceptible to a small degree to SAS and to 5-ASA and SP.
Conclusions: The intestinal D. desulfuricans strains differed in their susceptibility to SAS and its biotransformation products. The strains showing higher susceptibility to SAS lost the ability to reduce the azo bond in this drug, which may be attributed to the lower metabolic activity of the bacteria. The presence of D. desulfuricans in the large intestines of patients with ulcerative colitis and the confirmed diversity of the biological activity of the isolated strains demonstrate the need for clinical examination of the role of these bacteria in the development of some inflammatory disorders.
Keywords: Biotransformation, Cell Division - drug effects, Desulfovibrio desulfuricans - cytology, Desulfovibrio desulfuricans - drug effects, Desulfovibrio desulfuricans - physiology, Drug Resistance, Bacterial, Intestines - microbiology, Mesalamine - pharmacology, Sulfapyridine - pharmacology, Sulfasalazine - metabolism, Sulfasalazine - pharmacology, Biotransformation, Cell Division - drug effects, Desulfovibrio desulfuricans - physiology, Drug Resistance, Bacterial, Intestines - microbiology, Mesalamine - pharmacology, Sulfapyridine - pharmacology, Sulfasalazine - pharmacology
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.947703
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Database Analysis
Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter AccessMed Sci Monit In Press; DOI: 10.12659/MSM.947298
Clinical Research
Intraoperative Renal Near-Infrared Spectroscopy Monitoring as a Predictor of Renal Outcomes in Cardiac SurgeryMed Sci Monit In Press; DOI: 10.12659/MSM.947462
Most Viewed Current Articles
17 Jan 2024 : Review article 7,094,149
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,321
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,595
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,787
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912